featured-image news review


Online Neurology Education for Primary Care
E-Brain, developed with the Joint Neurosciences Council (a UK registered charity, of which P-CNS are members) continues to develop and offer excellent education modules to complete online and for which you receive CPD points. There a modules on headaches (developed with the input of Dr Andy Dowson, who was our Chair for many years), epilepsy and movement disorders to name but a few. What is more, you can access e-brain for free once you join the Primary Care Neurology Society, which we hope you will consider, if you’ve not already joined us. The joining fees we receive (one-off fee of £45) are a significant help in funding the running of the society.

If you want to read more about the recent e-brain developments, please click here. If you wish to join us, then please register via our website, Once we receive your joining fee, which can be paid online, we will activate your access to our website and also send your details to have you set up with an e-brain account.

Neurology education with MIMS Learning
You may also be interested to learn of the Neurology Learning Plan from MIMS Learning.  Learning plans provide key learning points on diagnosis, management, follow-up and referral. You can undertake the whole plan to demonstrate that you have studied this area in depth, or use individual modules from the plan to complement your existing learning. For details of this plan and the topic covered click here.

Clinical News

Sleep duration and risk of CVD and Stroke Mortality
A study presented at the Sleep Research Society annual meeting in Boston which collected data from over 1700 patients has found that cardiovascular and cerebrovascular mortality risks significantly increased in individuals with short duration sleep (classed as less then 6 hours) but not in individuals with normal sleep duration. The researchers suggest “It is likely that adults with CVD or stroke and short sleep duration suffer from greater central autonomic and metabolic dysregulation,” They also stated that “Clinical trials should test whether lengthening sleep improves the long-term prognosis of adults with CVD or stroke.”

Polyneuropathy and Parkinson’s
Data from a study presented at the 2017 International Congress of Parkinson’s Disease and Movement Disorders has highlighted a lesser known issue with Parkinson’s, which is that polyneuropathy is fairly common, with an overall prevalence of 19% to 55% compared with 8% to 9% in people without Parkinson’s. However, the mechanism behind this prevalence is not clear. The recent study also the Parkinson’s Polyneuropathy (PD-PNP) is independently associated with cognitive impairment (P =.008), autonomic dysfunction (P =.035), nonmotor symptoms (P =.042), and axial motor features (P =.045) compared with those without PD-PNP. Further details of this study can be found from here.

Gut Microbiota, metabolic syndrome and progression of Parkinson’s
Another study presented at the 2017 International Congress of Parkinson’s Disease and Movement Disorders has highlighted a growing interest in a the capacity of the microbiota to impact on neurological conditions. The data from the study presented suggest that “an imbalance in gut microbiota at baseline may be associated with the progression of Parkinson’s disease at 2-year follow-up. You can read more about this study from here. In a related study progression of Parkinson’s has also been linked to Metabolic Syndrome. Details of that study can be found here

Migraine – is zolmatriptan nasal spray (ZNS) an effective treatment in adolescents?
A paper presented at 2017 American Headache Society, which reported on a study of close to 800 adolescents found that treatment with ZNS, 5 mg significantly increased the percentage of patients who were pain-free at the 2-hour post-treatment mark compared with placebo (29.4%, placebo: 14.0%; P <05). To read more about this work click here

 Improved cognitive function in relapsing MS
A study presented at the 2017 Consortium of Multiple Sclerosis Centers Annual Meeting has shown that overall, treatment with ocrelizumab a new MS treatment improves cognitive performance in measures of processing speed and working memory better than interferon beta-1a. Full details of the study are available from here.

Published 10th July 2017.

To view previous news items please go to the news archive here